| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A T Bjerg, M Kristensen, C Ritz, K D Stark, J J Holst, T D Leser, A Wellejus, A Astru. Four weeks supplementation with Lactobacillus paracasei subsp. paracasei L. casei W8® shows modest effect on triacylglycerol in young healthy adults. Beneficial microbes. vol 6. issue 1. 2015-07-17. PMID:25245572. |
compared to placebo, l. casei w8 did not affect appetite, ad libitum energy intake, glp-1, glucose and insulin response and total, high-density or low-density lipoprotein cholesterol levels after four weeks intervention. |
2015-07-17 |
2023-08-13 |
human |
| Rachael Lennox, David W Porter, Peter R Flatt, Christian Holscher, Nigel Irwin, Victor A Gaul. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology. vol 86. 2015-07-14. PMID:24998752. |
(val(8))glp-1(glupal) monotherapy, or in combination with metformin, reduced circulating glucose (p < 0.05) and increased insulin (p < 0.05 to p < 0.01) concentrations, as well as improving glucose tolerance (p < 0.001) and glucose-stimulated insulin secretion (p < 0.05 to p < 0.01). |
2015-07-14 |
2023-08-13 |
mouse |
| Paula L McClean, Christian Hölsche. Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology. vol 86. 2015-07-14. PMID:25107586. |
the incretin hormone glucagon-like peptide-1 (glp-1) facilitates insulin signalling, and analogues such as liraglutide are on the market as treatments for type 2 diabetes. |
2015-07-14 |
2023-08-13 |
mouse |
| K Aaboe, S Akram, C F Deacon, J J Holst, S Madsbad, T Kraru. Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors. Diabetes, obesity & metabolism. vol 17. issue 1. 2015-07-14. PMID:25243647. |
to examine whether 12 weeks of treatment with a dipeptidyl peptidase-4 (dpp-4) inhibitor, sitagliptin, influences the insulin secretion induced by glucose, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) during a hyperglycaemic clamp in patients with type 2 diabetes (t2dm). |
2015-07-14 |
2023-08-13 |
Not clear |
| Lijie Liu, Fanfan Wang, Haiying Lu, Xiaomei Ren, Jihong Zo. Chromanol 293B, an inhibitor of KCNQ1 channels, enhances glucose-stimulated insulin secretion and increases glucagon-like peptide-1 level in mice. Islets. vol 6. issue 4. 2015-07-14. PMID:25437377. |
genetic studies suggest that altered incretin glucagon-like peptide-1 (glp-1) secretion might be a potential link between kcnq1 variants and impaired insulin secretion, but this hypothesis has not been verified so far. |
2015-07-14 |
2023-08-13 |
mouse |
| Lijie Liu, Fanfan Wang, Haiying Lu, Xiaomei Ren, Jihong Zo. Chromanol 293B, an inhibitor of KCNQ1 channels, enhances glucose-stimulated insulin secretion and increases glucagon-like peptide-1 level in mice. Islets. vol 6. issue 4. 2015-07-14. PMID:25437377. |
along with the potentiated insulin secretion during oral glucose tolerance tests (ogtt), plasma glp-1 level after gastric glucose load was increased in 293b treated mice. |
2015-07-14 |
2023-08-13 |
mouse |
| Lijie Liu, Fanfan Wang, Haiying Lu, Xiaomei Ren, Jihong Zo. Chromanol 293B, an inhibitor of KCNQ1 channels, enhances glucose-stimulated insulin secretion and increases glucagon-like peptide-1 level in mice. Islets. vol 6. issue 4. 2015-07-14. PMID:25437377. |
these data not only provided new evidence for the participation of kcnq1 in gsis at the level of pancreatic islet and intact animal but also indicated the potential linking role of glp-1 between kcnq1 and insulin secretion. |
2015-07-14 |
2023-08-13 |
mouse |
| Thomas Aranias, Alexandra Grosfeld, Christine Poitou, Amal Ait Omar, Maude Le Gall, Sylvie Miquel, Kévin Garbin, Agnès Ribeiro, Jean-Luc Bouillot, André Bado, Edith Brot-Laroche, Karine Clément, Armelle Leturque, Sandra Guilmeau, Patricia Serrada. Lipid-rich diet enhances L-cell density in obese subjects and in mice through improved L-cell differentiation. Journal of nutritional science. vol 4. 2015-07-09. PMID:26157580. |
the enterohormone glucagon-like peptide-1 (glp-1) is required to amplify glucose-induced insulin secretion that facilitates peripheral glucose utilisation. |
2015-07-09 |
2023-08-13 |
mouse |
| Annayya R Aroor, James R Sowers, Guanghong Jia, Vincent G DeMarc. Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system. American journal of physiology. Heart and circulatory physiology. vol 307. issue 4. 2015-07-08. PMID:24929856. |
two known substrates of dpp-4 include the incretin hormones glucagon-like peptide-1 (glp-1) and gastric inhibitory peptide, which are secreted by enteroendocrine cells in response to postprandial hyperglycemia and account for 60–70% of postprandial insulin secretion. |
2015-07-08 |
2023-08-13 |
Not clear |
| Liehua Liu, Bilal Omar, Piero Marchetti, Bo Ahré. Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets. Biochemical and biophysical research communications. vol 453. issue 3. 2015-07-08. PMID:25268763. |
ins-1 832/13 cells also expressed dpp-4, and inhibition of dpp-4 enhanced insulin secretion in the presence of glucagon-like peptide-1 (glp-1) in the cells. |
2015-07-08 |
2023-08-13 |
mouse |
| Tara A Schwetz, Christopher A Reissaus, David W Pisto. Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PloS one. vol 9. issue 11. 2015-07-08. PMID:25401335. |
differential stimulation of insulin secretion by glp-1 and kisspeptin-10. |
2015-07-08 |
2023-08-13 |
Not clear |
| Tara A Schwetz, Christopher A Reissaus, David W Pisto. Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PloS one. vol 9. issue 11. 2015-07-08. PMID:25401335. |
the gpcr ligands kisspeptin-10 (kp) and glucagon-like peptide-1 (glp-1) potentiate insulin secretion through gq and gs-coupled receptors, respectively. |
2015-07-08 |
2023-08-13 |
Not clear |
| Tara A Schwetz, Christopher A Reissaus, David W Pisto. Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PloS one. vol 9. issue 11. 2015-07-08. PMID:25401335. |
despite many studies, the signaling mechanisms by which kp and glp-1 potentiate insulin release are not thoroughly understood. |
2015-07-08 |
2023-08-13 |
Not clear |
| Tara A Schwetz, Christopher A Reissaus, David W Pisto. Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PloS one. vol 9. issue 11. 2015-07-08. PMID:25401335. |
kp significantly increases the cellular redox potential, while no effect is observed with glp-1, suggesting that kp and glp-1 potentiate insulin secretion through different mechanisms. |
2015-07-08 |
2023-08-13 |
Not clear |
| Tara A Schwetz, Christopher A Reissaus, David W Pisto. Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PloS one. vol 9. issue 11. 2015-07-08. PMID:25401335. |
co-treatment with kp and the gβγ-subunit inhibitor gallein inhibits insulin secretion similar to that observed with gallein alone, while co-treatment with gallein and glp-1 does not differ from glp-1 alone. |
2015-07-08 |
2023-08-13 |
Not clear |
| Tara A Schwetz, Christopher A Reissaus, David W Pisto. Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PloS one. vol 9. issue 11. 2015-07-08. PMID:25401335. |
in contrast, co-treatment with the gβγ activator msirk and either kp or glp-1 stimulates insulin release similar to msirk alone. |
2015-07-08 |
2023-08-13 |
Not clear |
| Tara A Schwetz, Christopher A Reissaus, David W Pisto. Differential stimulation of insulin secretion by GLP-1 and Kisspeptin-10. PloS one. vol 9. issue 11. 2015-07-08. PMID:25401335. |
these data suggest that kp likely alters insulin secretion through a gβγ-dependent process that stimulates glucose metabolism without altering ca(2+) activity, while glp-1 does so, at least partly, through a gα-dependent pathway that is independent of both metabolism and ca(2+). |
2015-07-08 |
2023-08-13 |
Not clear |
| Rüdiger Siekmeier, Thomas Hofmann, Gerhard Scheuch, Mieczyslaw Pokorsk. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome. Advances in experimental medicine and biology. vol 849. 2015-07-07. PMID:25427821. |
one of these, the incretin glucagon-like peptide 1 (glp-1), like insulin, needs subcutaneous administration causing inconvenience to patients. |
2015-07-07 |
2023-08-13 |
Not clear |
| Rüdiger Siekmeier, Thomas Hofmann, Gerhard Scheuch, Mieczyslaw Pokorsk. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome. Advances in experimental medicine and biology. vol 849. 2015-07-07. PMID:25427821. |
recently, another inhalative insulin (afrezza(®)) received market approval and glp-1 may serve as another candidate drug for inhalative administration. |
2015-07-07 |
2023-08-13 |
Not clear |
| Hui Wu, Chunhua Sui, Hui Xu, Fangzhen Xia, Hualing Zhai, Huixin Zhang, Pan Weng, Bing Han, Sichun Du, Yingli L. The GLP-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp. Journal of diabetes research. vol 2014. 2015-07-07. PMID:25580440. |
the glp-1 analogue exenatide improves hepatic and muscle insulin sensitivity in diabetic rats: tracer studies in the basal state and during hyperinsulinemic-euglycemic clamp. |
2015-07-07 |
2023-08-13 |
rat |